- •The Sclera
- •Preface
- •Contents
- •1.1 Introduction
- •1.2 Development of the Sclera
- •1.2.1.1 First Week
- •1.2.1.2 Second Week
- •1.2.1.3 Third Week
- •1.2.1.4 Fourth Week
- •1.2.1.5 Fifth Week
- •1.2.1.6 Sixth Week
- •1.2.1.7 Seventh Week
- •1.2.1.8 Ninth Week
- •1.2.1.9 Tenth Week
- •1.2.1.10 Thirteenth Week
- •1.2.1.11 Sixteenth Week
- •1.2.1.12 Twenty-Fourth Week
- •1.2.2.1 Collagens
- •1.2.2.2 Proteoglycans
- •1.2.2.3 Glycoproteins
- •1.3 Anatomy
- •1.3.1 Gross and Microscopic Anatomy
- •1.3.1.1 Scleral Foramina
- •Anterior Scleral Foramen
- •Posterior Scleral Foramen
- •1.3.1.2 Layers of the Sclera
- •Episclera
- •Scleral Stroma
- •Lamina Fusca
- •1.3.1.3 Blood Supply and Emissary Canals
- •Vascular Distribution
- •Circulatory Dynamics
- •1.3.1.4 Nerve Supply
- •1.3.2 Ultramicroscopic Anatomy
- •1.3.2.1 Sclera
- •1.3.2.2 Vessels
- •1.4 Biochemistry
- •1.5 Immunohistochemistry
- •1.6 Biomechanics
- •1.7 Molecular Structure
- •1.7.1 Collagen
- •1.7.2 Elastin
- •1.7.3 Proteoglycans
- •1.7.4 Glycoproteins
- •1.7.6 Fibroblast Growth Regulation
- •1.8 Summary
- •References
- •2.1 General Immune Response Considerations
- •2.1.1 Components of the Adaptive Immune Response
- •2.1.1.1 Lymphocytes
- •T Lymphocytes
- •B Lymphocytes
- •Third-Population Lymphocytes or Null Lymphocytes
- •2.1.1.2 Monocytes/Macrophages
- •Phagocytosis
- •Antigen-Presenting Cells
- •2.1.1.3 Polymorphonuclear Granulocytes
- •Neutrophils
- •Eosinophils
- •Basophils/Mast Cells
- •2.1.1.4 Platelets
- •2.1.2 Immunoregulation
- •2.1.2.1 Major Histocompatibility Complex
- •2.1.2.2 Humoral Mechanisms: Antibodies
- •2.1.2.3 Cellular Mechanisms
- •2.1.2.4 Summary
- •2.1.3 Abnormalities of the Immune Response
- •2.1.3.1 Hypersensitivity Reactions
- •Type III Hypersensitivity Reactions
- •Systemic Immune Complex Disease
- •Local Immune Complex Disease (Arthus Reaction)
- •Type IV Hypersensitivity Reactions
- •2.1.3.2 Autoimmunity
- •Mechanisms of Autoimmunity
- •2.2 Connective Tissue and the Immune Response
- •2.2.1 Fibroblast Functions and the Immune Response
- •2.3 The Sclera and the Immune Response: Scleritis
- •2.3.1 Immune Characteristics of the Sclera
- •2.3.2 The Susceptible Host: Immunogenetics
- •2.3.3 Etiology
- •2.3.3.1 Exogenous Agents
- •Viruses
- •Mycobacteria
- •2.3.3.2 Endogenous Substances
- •Glycosaminoglycans
- •Collagen
- •2.3.4 Pathogenesis
- •2.4 Summary
- •References
- •3.1 Investigation of the Illness
- •3.1.1 Major Complaint and History of Present Illness
- •3.1.2 Past History
- •3.1.3 Family History
- •3.1.4 Past and Present Therapy History
- •3.1.5 Review of Systems
- •3.1.6 Systemic Examination
- •3.1.6.1 Head
- •3.1.6.2 Extremities
- •3.1.7 Ocular Examination
- •3.1.7.1 Episcleral and Scleral Examination
- •External Examination of the Eye in Daylight
- •Slit-Lamp Examination
- •Diffuse Illumination
- •Slit-Lamp Illumination
- •Red-Free Illumination
- •3.1.7.2 General Eye Examination
- •Visual Acuity
- •Pupils and Extraocular Muscles
- •Cornea
- •Anterior Uvea
- •Lens
- •Fundus
- •Intraocular Pressure
- •3.2 Diagnostic Tests
- •3.2.1 Blood Tests
- •3.2.1.1 Rheumatoid Factor
- •3.2.1.2 Anticyclic Citrullinated Peptide Antibodies
- •3.2.1.3 Antinuclear Antibodies
- •3.2.1.4 Antineutrophil Cytoplasmic Antibodies
- •3.2.1.5 Circulating Immune Complexes
- •Fluid-Phase Binding Assays
- •C1q-Binding Assay
- •Cell-Binding Assays
- •Raji Cell-Binding Assay
- •3.2.1.6 Complement
- •Quantitation Tests
- •Functional Tests
- •3.2.1.7 HLA Typing
- •3.2.1.8 Antibody Titers Against Infectious Organisms
- •3.2.1.9 Interferon-Gamma Release Assays (IGRAs)
- •3.2.2 Anterior Chamber Polymerase Chain Reaction Testing
- •3.2.3 Smears and Cultures
- •3.2.4 Skin Testing
- •3.2.5 Radiologic Studies
- •3.2.6.1 Anterior Segment Fluorescein Angiography Techniques
- •3.2.6.2 Normal Anterior Segment Fluorescein Angiography
- •Arterial Phase
- •Capillary Phase
- •Venous Phase
- •3.2.7 Anterior Segment Indocyanine Green Angiography
- •3.2.8 Other Imaging Studies
- •3.2.8.1 Ultrasonography
- •A-Scan Ultrasonography
- •B-Scan Ultrasonography
- •High-Frequency Ultrasound Biomicroscopy
- •3.2.8.2 Optical Coherence Tomography
- •3.2.8.3 Computer Tomography Scanning
- •3.2.8.4 Magnetic Resonance Imaging
- •3.3 Biopsy
- •3.3.1 Biopsy for Suspected Systemic Vasculitic Disease
- •3.4 Data Integration: Diagnosis
- •3.5 Therapeutic Plan
- •3.6 Summary
- •References
- •4.1 Episcleritis
- •4.1.1 Introduction
- •4.1.2 Patient Characteristics
- •4.1.3 Clinical Manifestations
- •4.1.4.1 Simple Episcleritis
- •4.1.4.2 Nodular Episcleritis
- •4.1.5 Associated Diseases
- •4.1.6 Precipitating Factors
- •4.2 Scleritis
- •4.2.1 Introduction
- •4.2.2 Patient Characteristics
- •4.2.3 Clinical Manifestations
- •4.2.4.1 Diffuse Anterior Scleritis
- •4.2.4.2 Nodular Anterior Scleritis
- •Differential Diagnosis
- •Paralimbic Scleromalacia
- •Senile Scleral Hyaline Plaques
- •4.2.4.5 Posterior Scleritis
- •Symptoms and Signs
- •Fundus Findings
- •Choroidal Folds
- •Subretinal Mass
- •Disk Edema and Macular Edema
- •Annular Ciliochoroidal Detachment and Serous Retinal Detachment
- •Associated Diseases
- •Complications
- •Ancillary Tests
- •Ultrasonography
- •Computerized Tomography (CT) Scanning
- •Fluorescein Angiography
- •Differential Diagnosis
- •Proptosis, Chemosis, Lid Swelling, and Limitation of Ocular Movements
- •Subretinal Mass
- •Choroidal Folds
- •Annular Ciliochoroidal Detachment and/or Serous Retinal Detachment
- •Disk and Macular Edema
- •4.2.5 Associated Diseases
- •4.2.6 Complications of Scleritis
- •4.2.6.1 Keratopathy
- •Peripheral Corneal Thinning
- •Stromal Keratitis
- •Peripheral Ulcerative Keratitis
- •4.2.6.2 Uveitis
- •4.2.6.3 Glaucoma
- •Angle-Closure Glaucoma
- •Open-Angle Glaucoma
- •Neovascular Glaucoma
- •4.2.6.4 Cataract
- •4.3 Summary
- •References
- •5: Pathology in Scleritis
- •5.1.3 Fibrinoid Necrosis
- •5.2.1 Pathology of Episcleritis
- •5.2.2 Pathology of Scleritis
- •5.2.2.1 Noninfectious Scleritis
- •Sclera
- •Cells
- •Extracellular Matrix
- •Vessels
- •Episclera
- •Conjunctiva
- •Iris, Ciliary Body, and Choroid
- •Cornea
- •Other Ocular Structures
- •Polyarteritis Nodosa
- •Allergic Granulomatous Angiitis (Churg–Strauss Syndrome)
- •Granulomatosis with Polyangiitis (Wegener)
- •Connective Tissue Diseases
- •Clinicopathological Correlates in Infectious Scleritis
- •Systemic Infections
- •Local Infections
- •5.3 Biopsy
- •5.3.1 Noninfectious Necrotizing Scleritis
- •5.3.2 Noninfectious Recurrent Diffuse or Nodular (Nonnecrotizing) Scleritis
- •5.3.3 Infectious Scleritis (Diffuse, Nodular, or Necrotizing Scleritis)
- •5.3.4 Biopsy Technique
- •5.4 Summary
- •References
- •6: Noninfectious Scleritis
- •6.1.1 Adult Rheumatoid Arthritis
- •6.1.1.1 Epidemiology
- •Signs and Symptoms of Joint Involvement
- •Extraarticular Systemic Manifestations
- •6.1.1.2 Systemic Manifestations
- •Onset
- •Tegument
- •Vessels
- •Lung
- •Heart
- •Nervous System
- •Lymph Nodes
- •Larynx
- •Felty’s Syndrome
- •Amyloidosis
- •Miscellaneous
- •6.1.1.3 Ocular Manifestations
- •Keratoconjunctivitis Sicca
- •Scleritis
- •Keratitis
- •Anterior Uveitis
- •Glaucoma
- •Cataract
- •Retinal, Choroidal, and Optic Nerve Changes
- •Motility Disturbances
- •Episcleritis
- •6.1.1.4 Laboratory Findings
- •Rheumatoid Factor
- •Antibodies to Cyclic Citrullinated Polypeptides
- •Complete Blood Count
- •Acute-Phase Reactants
- •Synovial Fluid Analysis
- •Circulating Immune Complexes
- •Antinuclear Antibodies
- •Complement
- •Cryoglobulins
- •Radiographic Evaluation
- •Diagnosis
- •6.1.2 Systemic Lupus Erythematosus
- •6.1.2.1 Epidemiology
- •6.1.2.2 Systemic Manifestations
- •Musculoskeletal
- •Tegument
- •Vessels
- •Kidney
- •Hearth
- •Nervous System
- •Lung
- •Miscellaneous
- •6.1.2.3 Ocular Involvement
- •Scleritis
- •Episcleritis
- •Other Ocular Findings
- •6.1.2.4 Laboratory Findings
- •6.1.2.5 Diagnosis
- •6.1.3 Ankylosing Spondylitis
- •6.1.3.1 Epidemiology
- •6.1.3.2 Systemic Manifestations
- •Articular Involvement
- •Extraarticular Systemic Manifestations
- •6.1.3.3 Ocular Manifestations
- •Anterior Uveitis
- •Scleritis
- •Episcleritis
- •6.1.3.5 Diagnosis
- •6.1.4 Reactive Arthritis (Reiter)
- •6.1.4.1 Epidemiology
- •6.1.4.2 Systemic Manifestations
- •Articular Involvement
- •Extraarticular Systemic Manifestations
- •6.1.4.3 Ocular Manifestations
- •Conjunctivitis
- •Anterior Uveitis
- •Scleritis
- •Episcleritis
- •Other Ocular Findings
- •6.1.4.4 Laboratory and Radiographic Findings
- •6.1.4.5 Diagnosis
- •6.1.5 Psoriatic Arthritis
- •6.1.5.1 Epidemiology
- •6.1.5.2 Systemic Manifestations
- •Skin and Articular Involvement
- •6.1.5.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.5.4 Laboratory and Radiographic Findings
- •6.1.5.5 Diagnosis
- •6.1.6.1 Epidemiology
- •6.1.6.2 Systemic Manifestations
- •Gastrointestinal and Articular Manifestations
- •6.1.6.3 Ocular Manifestations
- •Anterior Uveitis
- •Scleritis
- •Episcleritis
- •Keratitis
- •6.1.6.4 Laboratory and Joint Radiologic Findings
- •6.1.6.5 Diagnosis
- •6.1.7 Relapsing Polychondritis
- •6.1.7.1 Epidemiology
- •6.1.7.2 Systemic Manifestations
- •6.1.7.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.7.4 Laboratory Findings
- •6.1.7.5 Diagnosis
- •6.1.8 Polyarteritis Nodosa
- •6.1.8.1 Epidemiology
- •6.1.8.2 Systemic Manifestations
- •6.1.8.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.8.4 Laboratory and Angiographic Findings
- •6.1.8.5 Diagnosis
- •6.1.9.1 Epidemiology
- •6.1.9.2 Systemic Manifestations
- •6.1.9.3 Ocular Manifestations
- •6.1.9.4 Laboratory Findings
- •6.1.9.5 Diagnosis
- •6.1.10 Granulomatosis with Polyangiitis (Wegener)
- •6.1.10.1 Epidemiology
- •6.1.10.2 Clinical Manifestations
- •6.1.10.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.10.4 Laboratory Findings
- •6.1.10.5 Diagnosis
- •6.1.11 Adamantiades–Behçet’s Disease
- •6.1.11.1 Epidemiology
- •6.1.11.2 Systemic Manifestations
- •6.1.11.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.11.4 Laboratory Findings
- •6.1.11.5 Diagnosis
- •6.1.12 Giant-Cell Arteritis
- •6.1.12.1 Epidemiology
- •6.1.12.2 Systemic Manifestations
- •6.1.12.3 Ocular Manifestations
- •Scleritis
- •6.1.12.4 Laboratory Findings
- •6.1.12.5 Diagnosis
- •6.1.13 Cogan’s Syndrome
- •6.1.13.1 Clinical Manifestations
- •Scleritis
- •Episcleritis
- •6.1.13.2 Laboratory Findings
- •6.2.1 Rosacea
- •6.3.1 Gout
- •6.5 Chemical Injury-Associated Scleritis
- •6.6 Summary
- •References
- •7: Infectious Scleritis
- •7.1 Bacterial Scleritis
- •7.1.1.1 Pathogenesis
- •7.1.1.2 Organisms
- •7.1.1.3 Management
- •7.1.1.4 Therapy
- •7.1.1.5 Prognosis
- •7.1.1.6 Our Experience
- •7.1.2 Mycobacterial Scleritis
- •7.1.2.1 Atypical Mycobacterial Disease
- •7.1.2.2 Tuberculosis
- •7.1.2.3 Leprosy
- •7.1.3 Spirochetal Scleritis
- •7.1.3.1 Syphilis
- •Epidemiology
- •Pathogenesis and Clinical Features
- •Scleritis and Episcleritis
- •Diagnosis
- •Therapy
- •7.1.3.2 Lyme Disease
- •Epidemiology
- •Pathogenesis and Clinical Features
- •Scleritis and Episcleritis
- •Diagnosis
- •7.1.3.3 Treatment
- •7.1.4 Chlamydial Scleritis
- •7.1.5 Actinomycetic Scleritis
- •7.1.5.1 Nocardiosis
- •7.2 Fungal Scleritis
- •7.2.1 Filamentous and Dimorphic Fungal Scleritis
- •7.2.1.1 Pathogenesis
- •7.2.1.2 Organisms
- •7.2.1.3 Management
- •7.2.1.4 Therapy
- •7.2.1.5 Our Experience
- •7.3 Viral Scleritis
- •7.3.1 Herpes Scleritis
- •7.3.1.1 Herpes Zoster Scleritis
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Scleritis
- •Episcleritis
- •Diagnosis
- •Treatment
- •7.3.1.2 Herpes Simplex Scleritis
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Scleritis
- •Episcleritis
- •Diagnosis
- •Therapy
- •Our Experience
- •7.3.2 Mumps Scleritis
- •7.4 Parasitic Scleritis
- •7.4.1 Protozoal Scleritis
- •7.4.1.1 Acanthamoeba
- •7.4.1.2 Toxoplasmosis
- •7.4.2 Helminthic Scleritis
- •7.4.2.1 Toxocariasis
- •7.5 Summary
- •References
- •8.1 Scleral Deposits
- •8.1.1 Scleral Protein Deposition
- •8.1.1.1 Porphyria
- •8.1.1.2 Cystinosis
- •8.1.1.3 Alkaptonuria
- •8.1.1.4 Amyloidosis
- •8.1.2 Scleral Lipid Deposition
- •8.1.2.1 Familial Hypercholesterolemia and Histiocytosis X
- •8.1.2.2 Age-Related Degeneration
- •8.1.3 Scleral Carbohydrate Deposition
- •8.1.3.1 Mucopolysaccharidosis
- •8.1.4 Scleral Mineral Deposition: Calcium
- •8.1.4.1 Hyperparathyroidism
- •8.1.4.2 Other Causes of Hypercalcemia
- •8.1.4.3 Age-Related Degeneration
- •Senile Scleral Hyaline Plaques
- •8.1.5 Scleral Pigment Deposition: Bilirubin
- •8.1.5.1 Jaundice
- •8.2 Scleral Thinning (Blue Sclerae)
- •8.2.1 Scleral Thinning in Inherited or Congenital Diseases
- •8.2.1.1 Marfan’s Syndrome
- •8.2.1.2 Osteogenesis Imperfecta
- •8.2.1.3 Pseudoxanthoma Elasticum
- •8.2.1.4 Ehlers–Danlos Syndrome
- •8.2.1.5 Keratoconus
- •8.2.1.6 Buphthalmos
- •8.2.1.7 Coloboma
- •8.2.1.8 Myopia
- •8.2.2 Scleral Thinning in Acquired Diseases
- •8.2.2.2 Paralimbal Scleromalacia
- •8.3 Scleral Thickening
- •8.3.1 Nanophthalmos
- •8.3.2 Scleropachynsis
- •8.3.3 Phthisis Bulbi
- •8.4 Scleral Tumors
- •8.4.1 Dermoid Choristomas
- •8.4.2 Epithelial Tumors
- •8.4.2.1 Papillomas or Intraepithelial Epitheliomas
- •8.4.2.2 Squamous Cell Carcinoma
- •8.4.3 Dense Connective Tissue Tumors
- •8.4.3.1 Nodular Fasciitis
- •8.4.3.2 Fibroma
- •8.4.3.3 Fibrous Histiocytoma
- •8.4.3.4 Sarcomas
- •8.4.4 Vascular Tumors
- •8.4.4.1 Hemangiomas
- •8.4.4.2 Lymphangiomas
- •8.4.5 Blood Cell Tumors
- •8.4.5.1 Leukemia
- •8.4.5.2 Lymphoma and Lymphosarcoma
- •8.4.6 Nervous Tumors
- •8.4.6.2 Neurilemmoma (Schwannoma)
- •8.4.7 Pigmented Tumors
- •8.4.7.1 Nevus
- •8.4.7.2 Melanocytoma
- •8.4.8 Secondary Tumors
- •8.5 Summary
- •References
- •9.1 Treatment of Episcleritis
- •9.2 Treatment of Scleritis
- •9.2.1 Medical Treatment
- •9.2.1.1 Rheumatoid Arthritis
- •9.2.1.2 Systemic Lupus Erythematosus
- •9.2.1.3 Polyarteritis Nodosa
- •9.2.1.4 Granulomatosis with Polyangiitis (Wegener)
- •9.2.1.5 Relapsing Polychondritis
- •9.2.1.7 Posterior Scleritis
- •9.2.1.8 Infectious Scleritis
- •9.2.2 Ancillary Therapy
- •9.2.3 Drug Management Responsibility
- •9.2.4 Surgical Treatment
- •9.3 Summary
- •References
- •Index
126 |
4 Clinical Considerations of Episcleritis and Scleritis |
|
|
be the problem whose diagnostic study leads to the discovery and subsequent treatment of a connective tissue disease or a vasculitic disease. When scleritis is the only presenting complaint, diagnosis and therapy of the potentially lethal systemic disease are often delayed. In our series, scleritis was the Þrst manifestation of connective tissue disease or a vasculitic disease in 48 patients (10%). The most common diagnosis eventually discovered was granulomatosis with polyangiitis (Wegener) followed by relapsing polychondritis. Meticulous review of systems (with subsequent studies to pursue leads) was the most fruitful diagnostic endeavor for establishing a diagnosis. Evaluation of biopsed tissue, and laboratory or X-ray studies in the context of review of system Þndings, conÞrmed the initial diagnostic impressions.
Systemic disease association was found to be most common in the necrotizing anterior types of scleritis, either with inßammation (80%) and without inßammation (67%), followed by the diffuse anterior (36%), nodular anterior (30%), and posterior (19%) types (Table 4.4). Diffuse anterior scleritis with inßammation was found to be the most frequent subcategory in patients whose scleritis appeared as a Þrst manifestation of a systemic disease (81%).
Although gout has been reported with scleritis, the association in most cases is vague and indeÞnite [18, 21]. Because erythema nodosum is a sign of other underlying diseases, such as bacterial (streptococcal), mycobacterial (tuberculosis), and chlamydial (psittacosis) infections, sarcoidosis, arthritis associated to inßammatory bowel disease, and Beh•etÕs disease, we have not considered it as a separate diagnostic entity, unlike other authors [2, 5]. Likewise, because RaynaudÕs phenomenon is a vascular manifestation present in several connective tissue and vasculitic diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and giant cell arteritis, we, unlike other authors [13], considered it as part of the primary systemic disease. Some patients with scleritis may give a past history of rheumatic heart disease, but the conditions have not been described as occurring at the same time [3].
4.2.6Complications of Scleritis
4.2.6.1 Keratopathy
Because corneal changes in scleritis appear as an extension of the adjacent scleral inßammation, the area most frequently involved is the corneal periphery. Peripheral corneal involvement may precede the onset of scleritis [143, 144]. The different patterns of corneal involvement are related to the severity and type of the scleral inßammation and they can be classiÞed, depending on whether or not thinning, inÞltration, or ulceration of the peripheral cornea occurs.
Peripheral Corneal Thinning
Peripheral corneal thinning is the most benign form of corneal involvement associated with scleritis. It is frequently associated with diffuse anterior scleritis and, although it may occur in young patients without any systemic condition, it is often found in middle-aged and elderly individuals with long-standing rheumatoid arthritis [2]. The peripheral cornea becomes grayish and thinned in one or more areas over a period of several years, eventually extending through the full circumference of the eye (Fig. 4.34). The gutter, usually about one-third thinner than the normal central cornea, does not extend more than 2 mm centrally and is not necessarily located in the same quadrant as the area of scleral inßammation. Because the central area remains unaffected, there is little effect on visual acuity. The epithelium remains intact throughout the thinning process, but vascularization, lipid deposition, and further opaciÞcation and thinning may eventually involve the edematous stroma. Deepening of the gutter may result in a progressive astigmatism that interferes with visual acuity. If some pain occurs, it is due to the scleral inßammation rather than the peripheral corneal thinning. Sometimes, the thinned cornea may progress to an area of ectasia. Spontaneous perforation is rare, although trauma can rupture the thin cornea. Peripheral corneal thinning may also occur without scleritis in patients with long-standing rheumatoid arthritis; [145Ð148] circumferential thinning with a well-demarcated central edge without lipid deposition and minimal vascularization resembles the
4.2 Scleritis |
127 |
|
|
Fig. 4.34 Slit-lamp photomicrograph. Note the area in the inferior cornea of peripheral corneal thinning in this patient, who has had multiple bouts of diffuse anterior scleritis
Fig. 4.35 TerrienÕs marginal degeneration. Note the quiet eye, the area of corneal thinning in the superior 160¡ of the corneal periphery, and the lipid/protein deposits in the corneal stroma at the anterior border of the area of active thinning
appearance of an eye wearing a hard contact lens (Òcontact lensÓ cornea) [149].
The differential diagnosis of peripheral corneal thinning associated with scleritis includes TerrienÕs marginal degeneration (Fig. 4.35), pellucid marginal degeneration, and senile furrow degeneration (Table 4.10). All of these are slowly progressive, bilateral, and painless peripheral stromal thinning with intact epithelium. In all of these, there is rare loss of vision or central cornea involvement. Furthermore, in peripheral corneal thinning associated with scleritis and in TerrienÕs marginal degeneration, the peripheral gutter may have lipid deposition and vascularization. However, TerrienÕs marginal degeneration usually occurs superiorly and, although an atypical pterygium may be present in 20% of the cases, it is not associated with true scleritis [150, 151]. Peripheral corneal thinning associated with scleritis may account for some cases considered to be Òinßammatory TerrienÕs marginal corneal disease.Ó [152] Unlike peripheral corneal thinning associated with scleritis, pellucid marginal degeneration is a noninßammatory condition that affects only the inferior cornea and is not accompanied by lipid deposition or vascularization [153, 154]. Finally, in senile furrow degeneration, a peripheral corneal thinning of the clear interval between an arcus senilis and the limbus, there is neither vascularization and lipid inÞltration in the
narrow gutter (0.5 mm or less in width) nor adjacent scleral inßammation [155, 156]. Unlike peripheral corneal thinning associated with scleritis, TerrienÕs marginal degeneration, pellucid marginal degeneration, and senile furrow degeneration are not associated with any systemic disease.
Suppression of the scleral inßammation usually allows regression, but in some patients the defect remains. Lubrication or therapeutic soft contact lens may prove effective in some patients. In cases of astigmatic error, spectacles or rigid contact lens may be used, depending on the severity. Progression to a thinned, ectatic cornea may be treated by cyanoacrylate glue application with or without conjunctival resection or by excising the ectatic tissue and replacing it with an annular lamellar keratoplasty or with a conjunctival ßap.
Stromal Keratitis
Extension of the diffuse, nodular, or necrotizing scleral inßammation into the cornea may appear as isolated or multiple white or gray nummular midstromal opacities, which usually are in the periphery, although they can involve the central cornea. The opacities are usually in the same quadrant as the scleral inßammation; therefore, the corneal involvement in the diffuse type of scleritis is usually more extensive than in the nodular type. If the treatment for the scleritis is
128 |
|
4 Clinical Considerations of Episcleritis and Scleritis |
||
|
|
|||
Table 4.10 Differential diagnosis of peripheral corneal thinning associated with scleritis |
|
|||
|
|
|
|
|
|
Peripheral corneal |
TerrienÕs marginal |
Pellucid marginal |
Senile furrow |
Parameter |
thinning scleritis |
degeneration |
degeneration |
degeneration |
|
|
|
|
|
Age predilection |
Middle aged and elderly |
Young and |
Young and |
Old |
|
|
middle aged |
middle aged |
|
Sex predilection |
Female |
Male |
− |
− |
|
|
|
|
|
Laterality |
Bilateral |
Bilateral |
Bilateral |
Bilateral |
|
|
|
|
|
Pain |
− |
− |
− |
− |
Visual loss |
± |
± |
± |
− |
Epithelial defect |
− |
− |
− |
− |
|
|
|
|
|
Stromal thinning |
+ |
+ |
+ |
+ |
|
|
|
|
|
Progression |
Slow |
Slow |
Slow |
Slow |
Location |
Circumferential |
Superior |
Inferior |
Circumferential |
Width (mm) |
1Ð2 |
1Ð2 |
1Ð2 |
0.5 or less |
|
|
|
|
|
Central edge |
Eventually lipids |
GrayÐwhite line |
Protruding |
Arcus senilis (lipid) |
Gutter lipids |
Eventually develop |
+ |
− |
− (lucid interval) |
Gutter vessels |
Eventually develop |
+ |
− |
− |
|
|
|
|
|
Scleral/conjunctival |
+ (mild to moderate) |
± (occasional |
− |
− |
inßammation |
|
atypical pterygium) |
|
|
Perforation |
± |
± |
± |
− |
|
|
|
|
|
Associated disease |
Systemic disease |
− |
− |
− |
|
(rheumatoid arthritis) |
|
|
|
|
|
|
|
|
Treatment |
Scleritis treatment |
Contact lenses |
Contact lenses |
− |
|
Contact lenses |
Tectonic |
Tectonic |
|
|
Tectonic keratoplasty |
keratoplasty |
keratoplasty |
|
|
Conjunctival ßap |
|
|
|
delayed, the lesions may expand toward the center of the cornea and eventually coalesce so that large areas may become opaque and swollen, leading to an appearance resembling that of the sclera (ÒsclerosingÓ changes) (Fig. 4.36). Vessels may involve the superÞcial stroma, but they are always far behind the advancing edge of the opacity. Lipid deposition in the stromal opacities can be seen as crystalline deposits (Òcandy ßossÓ) [2].
The opacities may disappear completely with early and vigorous treatment of the scleral inßammation; more often, only partial regression occurs, leaving permanent changes that, if central, may require penetrating corneal grafting for visual restoration.
Peripheral Ulcerative Keratitis
The most severe form of keratitis associated with scleritis is PUK, a potentially devastating process in which the layers of the peripheral cornea are progressively destroyed, leaving the cornea so thin that it can easily perforate. The destructive
Fig. 4.36 Slit-lamp photomicrograph: peripheral sclerosing keratitis. Note the peripheral keratitis with associated neovascularization and opaciÞcation of the peripheral cornea in this patient, who has had chronic anterior scleritis
process, usually associated with necrotizing scleritis, begins as a gray, swollen, inÞltrated area adjacent to a region of scleral inßammation that in a few days may break down, leaving only some layers of deep stroma and/or DescemetÕs
